Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
MapLight Therapeutics, Inc. ( (MPLT) ) has shared an update.
MapLight Therapeutics reported first-quarter 2026 results on May 14, highlighting an expanded clinical pipeline in schizophrenia, Alzheimer’s disease psychosis and autism spectrum disorder alongside rising operating expenses and losses. The company completed enrollment in its Phase 2 ZEPHYR trial for schizophrenia, finished the last patient visit in the Phase 2 IRIS trial in autism, and continued enrolling patients in the Phase 2 VISTA trial in Alzheimer’s psychosis, while ending the quarter with $395.2 million in cash, which management expects will fund operations through 2027 but reflects significantly higher R&D and G&A spending and a wider net loss year over year.
Research and development costs rose to $53.7 million from $19.8 million a year earlier, and general and administrative expenses nearly tripled to $10.8 million, driven mainly by increased clinical activity, headcount and stock-based compensation. Net loss widened to $60.7 million from $22.3 million in the prior-year quarter, underscoring the financial bet investors are making on upcoming mid-August 2026 topline data from the ZEPHYR and IRIS studies and longer-dated readouts from the VISTA trial, including the FDA Fast Track–designated Alzheimer’s psychosis program.
The most recent analyst rating on (MPLT) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on MapLight Therapeutics, Inc. stock, see the MPLT Stock Forecast page.
Spark’s Take on MPLT Stock
According to Spark, TipRanks’ AI Analyst, MPLT is a Neutral.
The score is primarily held back by pre-revenue financials with widening losses and rising cash burn despite a strong, lightly levered balance sheet. Technicals are supportive with clear uptrend signals, but valuation provides limited support due to a negative P/E and no dividend.
To see Spark’s full report on MPLT stock, click here.
More about MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing circuit-specific pharmacotherapies for debilitating central nervous system and neuropsychiatric disorders. Founded by leaders in psychiatry and neuroscience, the company uses a discovery platform aimed at identifying disease-linked neural circuits and targeting them for therapeutic modulation.
Average Trading Volume: 252,436
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.29B
See more data about MPLT stock on TipRanks’ Stock Analysis page.